Core Insights - Artelo Biosciences, Inc. has reported positive interim Phase 2 results for ART27.13, a treatment for cancer-related anorexia, showing significant weight gain in patients compared to placebo [2][6] - The company is advancing three differentiated clinical programs, with ART26.12 and ART27.13 attracting substantial partnering interest from pharmaceutical companies [2][3] - Financial results for Q3 2025 indicate a net loss of $3.1 million, with cash and investments totaling $1.7 million as of September 30, 2025 [11] Clinical Developments - ART27.13 demonstrated an average weight gain of +6.4% in patients versus a -5.4% loss in the placebo group, along with a +4.2% increase in lean body mass [6] - The multiple ascending dose (MAD) study for ART26.12 is being finalized to confirm safety and pharmacokinetics observed in the single ascending dose (SAD) study [3][6] - The first-in-human study for ART12.11 is expected to commence in the first half of 2026 [4] Financial Performance - Research and development expenses for Q3 2025 were $1.3 million, up from $0.3 million in the same period in 2024 [5] - General and administrative expenses increased to $1.8 million for Q3 2025, compared to $0.9 million in 2024 [11] - The company raised $3.0 million through a public offering in September 2025 and has an At-The-Market Offering Agreement for up to $6.5 million [11] Product Pipeline - ART26.12 is being developed as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy, with potential applications in various pathologies [7] - ART27.13 is a novel agent targeting peripheral CB1 and CB2 receptors, aimed at improving appetite and quality of life in cancer patients [8] - ART12.11, a proprietary cocrystal of CBD and TMP, has shown improved pharmacokinetics and efficacy compared to other CBD forms [10]

Core Insights - Artelo Biosciences, Inc. is advancing its clinical pipeline with multiple announcements of clinical data results anticipated in Q3 2025, focusing on treatments for cancer, pain, and neurological conditions [1] Business Highlights - ART26.12 is progressing towards a multi-dose Phase 1 safety study, with positive safety and pharmacokinetics demonstrated in a completed Phase 1 Single Ascending Dose (SAD) study [2][7] - ART27.13 is on track for a Phase 2 readout in Q3 2025, targeting cancer anorexia-cachexia syndrome, a condition with no FDA-approved therapies [3][11] - ART12.11 is showing promise in treating depression and cognitive decline, with plans to initiate human trials in early 2026 [4][8] Financial Results - For Q2 2025, the company reported a net loss of $3.2 million, or $5.61 per share, compared to a net loss of $2.4 million, or $4.52 per share in Q2 2024 [14] - Research and development expenses were $1.9 million for the quarter, up from $1.7 million in the same period in 2024, while general and administrative expenses increased to $1.3 million from $0.8 million [9] Cash and Investments - As of June 30, 2025, cash and investments totaled $2.1 million, with recent funding activities including $0.9 million in convertible notes and a private placement yielding $1.425 million [14] - Subsequent to June 30, 2025, the company completed a PIPE transaction for gross proceeds of $9.475 million, alongside a strategy to invest in the digital currency Solana [14][15]

Core Insights - Artelo Biosciences, Inc. is focused on developing treatments for cancer, pain, dermatologic, and neurological conditions through modulation of lipid-signaling pathways [1][12] - The company anticipates significant milestones for its lead programs within the next 12 months, including results from its Phase 1 safety trial of ART26.12 and initial results from the Phase 2 CAReS study for ART27.13 [3][6] Business Highlights - ART26.12, a lead candidate, is a Fatty Acid Binding Protein 5 (FABP5) inhibitor, cleared by the FDA for a first-in-human study, targeting chemotherapy-induced peripheral neuropathy (CIPN) [5][8] - The Phase 1 safety study for ART26.12 has completed enrollment, with data readout expected in Q2 2025 [6] - ART27.13 is being evaluated in the Phase 2 CAReS study for cancer-related anorexia and cachexia, with initial data expected in Q3 2025 [6][10] Financial Results - For Q1 2025, research and development expenses were $1.4 million, a slight decrease from $1.5 million in Q1 2024 [7] - General and administrative expenses were $1.0 million, down from $1.1 million in the same period last year [7] - The net loss for Q1 2025 was $2.4 million, or $0.72 per share, compared to a net loss of $2.5 million, or $0.78 per share, in Q1 2024 [7] Cash Position - As of March 31, 2025, cash and investments totaled $0.7 million [7] - In early May 2025, the company issued $0.9 million in at-market convertible notes to support operations until further financing is secured [7]